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We report three cases of invasive Geotrichum capitatum infection in patients with acute leukemia for which
an enzyme-linked immunosorbent assay (ELISA) for Aspergillus galactomannan was positive, with no evidence
of aspergillosis. Supernatants obtained from suspensions of 17G. capitatum strains gave positive reactions with
the Aspergillus galactomannan ELISA. These clinical and laboratory data seem to suggest that G. capitatum
produces a soluble antigen that is cross-reactive with Aspergillus galactomannan.
Aspergillus galactomannan detection by a sandwich enzyme-
linked immunosorbent assay (ELISA) is widely used through-
out the world in diagnosing invasive aspergillosis, and it has
been introduced among the international microbiological cri-
teria for the diagnosis of this fungal infection in immunocom-
promised hosts (2, 11). A major problem with the detection of
circulating galactomannan is the occurrence of false-positive
results, which, in some cases, have been shown to be related to
cross-reactivity with other opportunistic fungi (11). We report
cases of three acute-leukemia patients who developed dissem-
inated infection by Geotrichum capitatum for which ELISA for
Aspergillus galactomannan was positive, with no evidence of
aspergillosis.
Patient 1 was a 7-year-old child with acute lymphoblastic
leukemia in second relapse who underwent salvage chemother-
apy in February 2004. Ten days after this treatment, the patient
developed fever and periorbital edema; broad-spectrum anti-
biotics and liposomal amphotericin B were administered. A
week later, several serum samples were positive for galacto-
mannan antigen and caspofungin was added. A computed-
tomography scan showed an abscess of the cerebral base start-
ing from the ethmoidal plan and involving the hypophyseal
region. Therefore, a surgical debridement was performed; G.
capitatum was isolated from samples of pus, liquor, and bone
(identification was performed with the VITEK system [bio-
Merieux Italia, Rome, Italy]). Galactomannan antigen was de-
tected in the pus. Histology of a bone fragment disclosed
necrotic tissue in which mycotic invasion was evident. On pe-
riodic acid-Schiff- and Grocott-stained sections, the fungi con-
sisted of septate hyphae, slightly bent with parallel disposition
and only occasional branching at a wide acute angle or budding
at a right angle. A few spores and fragmentation of the myce-
lium in arthroconidia were also observed. Caspofungin was
replaced with voriconazole. Within a few days, the patient’s
clinical condition improved and galactomannan antigen, for
which tests were previously constantly positive, disappeared
from the blood. Two months after surgery, while under vori-
conazole treatment, the child underwent two consecutive aplo-
identical bone marrow transplants from his father and his
mother, but after a few weeks, the child died from sepsis of an
unknown origin. Serum galactomannan antigen was no longer
detected.
Patient 2 was a 9-year-old girl with a diagnosis of myelodys-
plasia secondary to acute lymphoblastic leukemia and who
underwent an allogeneic bone marrow transplant, receiving
bone marrow from her HLA-compatible sister. Seven months
later, she developed acute myeloblastic leukemia (AML) and
started intensive chemotherapy. Hematological remission was
not obtained, and 3 months after AML diagnosis (April 2005),
the girl underwent salvage cytotoxic treatment that resulted in
a very severe and prolonged aplasia, and antifungal prophylaxis
with caspofungin was started. After a week, she developed
fever, a cough, and papular skin lesions. Serum galactomannan
antigen was repeatedly detected at increasing concentrations,
and after a week, the girl died despite broad-spectrum antibi-
otic and antifungal treatment with caspofungin and liposomal
amphotericin B. The same day, G. capitatum was isolated from
multiple blood cultures performed during the febrile period.
Patient 3 was a 49-year-old man diagnosed with AML in
February 2006. After induction remission chemotherapy, he
developed fever and neutropenic and antibiotic treatment with
piperacillin-tazobactam was started. The fever disappeared af-
ter 48 h. Five days later, the patient was newly febrile, and a
computed-tomography scan showed a pulmonary infiltrate on
the left basal region associated with numerous micronodular
lesions without evidence of a halo sign. Antibiotic therapy with
piperacillin-tazobactam was replaced with treatment with a
combination of meropenem, teicoplanin, and amikacin. Three
days later, based on the persistence of fever and the appear-
ance of multiple little papular skin lesions highly suggestive of
candida infection, treatment with liposomal amphotericin B (5
mg/kg/day) was started. A serum sample was positive for ga-
lactomannan antigen, and cultures from blood and from a skin
lesion needle aspirate yielded a yeast morphologically compat-
ible with G. capitatum. Based on the previous experience with
the two above-described cases of G. capitatum infection, lipo-
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somal amphotericin B was replaced with voriconazole. Two
days later, identification of the G. capitatum yeast was con-
firmed with the VITEK system and a second serum sample was
positive for galactomannan antigen. After a week of voricon-
azole therapy, the patient developed a respiratory failure and
died despite broad-spectrum antibiotic and antifungal treat-
ment. A bronchoalveolar lavage sample was negative for fungi
and mycobacteria but yielded Stenotrophomonas maltophilia.
Two further serum samples were negative for galactomannan
antigen.
Despite the positive Platelia Aspergillus assay results for mul-
tiple samples from the three patients, the histopathological,
microbiological, and clinical findings suggested that coinfec-
tion by G. capitatum and Aspergillus spp. was unlikely. How-
ever, the possibility of an undetected Aspergillus infection cannot
be formally excluded because the patients did not undergo au-
toptic examination and Aspergillus PCR was not performed on
the available specimens. At the time of serum sample collec-
tion, the patients did not receive antibiotics, such as piperacil-
lin-tazobactam or amoxicillin-clavulanate, known to cause false
positivity in the Platelia Aspergillus assay (11). Therefore, we
hypothesized that Platelia Aspergillus positivity may have been
due to a cross-reaction with antigens released by G. capitatum.
Consequently, we tested 17 clinical strains of G. capitatum and
other control fungi for their reactivity in the ELISA assay,
according to a previously described procedure (4) (Table 1).
Cultures were plated on Sabouraud dextrose agar and incu-
bated at 30°C for 5 days. For each strain, 5 to 10 colonies were
suspended in 1 ml distilled water. After vigorous agitation, the
suspensions were centrifuged for 5 min at 10,000  g, and the
supernatants were heated and tested with Platelia Aspergillus.
Each experiment included several controls, i.e., distilled water
and negative, positive, and standard (1-ng/ml) serum samples
provided by the manufacturer. The ratio between the optical
density of the serum sample and that of the control standard
serum was calculated for each sample. According to the re-
cently suggested 0.5 cutoff value for the test, values of 0.5
were considered relevant (10). The 17 G. capitatum strains,
including the isolate from patient 3 (isolates from patients 1
and 2 were no longer available), showed various positive in-
dexes of reactivity (range, 1.2 to 5). The three Aspergillus
strains and the two strains of Cryptococcus neoformans showed
high and intermediate indexes of reactivity, respectively, in the
Platelia Aspergillus assay. The two reference Candida strains
did not show any reactivity.
The monoclonal antibody EB-A2, used both in the Pastorex
Aspergillus latex agglutination test and in the Platelia Aspergil-
lus assay, showed cross-reactivity with other fungi, bacteria,
drugs, foods, and cotton swabs (3, 8, 11–14). The occurrence
of false-positive results with the Aspergillus galactomannan
detection test for patients receiving antibiotics, in particular
piperacillin and amoxicillin either alone or combined with
-lactamase inhibitors, is a major drawback of this technique;
as such, results may lead to a false diagnosis of probable or
possible aspergillosis and unjustified antifungal therapy (3, 11).
This finding has forced some institutions to change their anti-
bacterial protocols and the FDA to issue a warning (5, 7).
False-positive reactivity in the Platelia Aspergillus assay has
also been observed in the context of an invasive infection
caused by other opportunistic fungal pathogens. The reactivi-
ties of the monoclonal antibody EB-A2 with the exoantigens of
some filamentous fungi other than Aspergillus spp. were docu-
mented several years ago, and further fungal pathogens have
been added to this series over the years (4, 8, 13, 14). Culture
supernatants of Trichophyton species, Botrytis species, Wall-
emia sebi, Cladosporium cladosporioides, Penicillium species,
Paecilomyces variotii, Acremonium species, Alternaria species,
and Fusarium species showed weak to strong reactivities with
the sandwich ELISA (8, 13, 14), and very recently, Cryptococ-
cus neoformans galactoxylomannan was also shown to be
cross-reactive with Aspergillus galactomannan (4). On the
other hand, only a few cases of non-Aspergillus fungal infec-
tions in whom the test for galactomannan was positive have
been reported to date: two human immunodeficiency virus-
positive patients, one with disseminated Penicillium marnef-
fei infection and one with cryptococcosis (4, 12), and one
blood stem cell transplant patient with a Hickman intrave-
nous line infection by Penicillium species (9).
Our three cases and in vitro studies show that G. capitatum
exoantigens may be cross-reactive in the Aspergillus galacto-
mannan assay. Although almost all of the yeast mannans do
not contain other carbohydrate components except a trace
of N-acetylglucosamine and glucose, some yeasts, including
Geotrichum spp., are known to have galactomannan as a cell
wall component (1), but until now, no data on detection of
circulating galactomannan in patients with invasive infection
due to this genus of yeasts have been published.
TABLE 1. Reactivities of soluble antigens from suspensions of
clinical and reference strains of G. capitatum and other
fungi in the Platelia Aspergillus assay
Species and strain Site of isolationb
Index of reactivity
in the Platelia
Aspergillus assay
A. fumigatus Rom BAL 5
A. fumigatus Mor Sputum 5
A. niger Tri Ear 5
C. albicans ATCC 90028 Reference strain 0.5
C. parapsilosis ATCC 22019 Reference strain 0.5
C. neoformans
Sob CSF 3.4
Imp CSF 2.9
G. capitatum
469 Urine 1.2
448 Blood 1.8
E202 Blood 2.2
PE2 Blood 1.9
BG2 Blood 1.8
Pisa Respiratory tract 3.2
116A Respiratory tract 1.9
434 Blood 1.2
114A Blood 1.5
Monica Respiratory tract 1.8
Palermo Dr Blood 1.9
Palermo Ma Blood 2.5
E299a Blood 5
ATCC 62963 Reference strain 2.3
ATCC 62964 Reference strain 1.9
ATCC 200927 Reference strain 2.7
ATCC 200925 Reference strain 1.7
a Isolate from patient 3.
b BAL, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid.
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G. capitatum, formerly known as Trichosporon capitatum or
Blastoschizomyces capitatus, is an uncommon, but frequently
fatal, cause of invasive infections in immunocompromised pa-
tients, particularly those with hematological malignancies (6).
In a recent retrospective multicenter study from Italy, the
incidence of G. capitatum infection among patients with acute
leukemia was 0.5%, with a 55.7% crude mortality rate (6).
Early diagnosis is difficult to establish because clinical symp-
toms are not specific and frequently resemble those of invasive
candidosis. Blood cultures, which are the “gold standard” for
diagnosis of invasive G. capitatum infections, are negative in
about 30% of cases and usually take several days to show
detectable growth of yeast cells. Therefore, noncultural meth-
ods could be useful for the improvement of laboratory diag-
nosis, but experiments on G. capitatum antigens or DNA de-
tection are not available to date. This false-positive reactivity in
the Platelia Aspergillus assay does not seem to constitute an
important problem for specificity in the diagnosis of invasive
aspergillosis, as the incidence of G. capitatum infections is very
low even in leukemic patients (6). On the contrary, this unex-
pected reactivity in the test could be considered a useful diag-
nostic and prognostic tool in the management of G. capitatum
infections. A positive galactomannan assay result for a patient
with an infective clinical picture suggestive of Candida infec-
tion could indicate the possibility of a G. capitatum infection,
considering also that galactomannan serum detection may pre-
cede by several days the microbiological documentation of the
infection (for patients 1, 2, and 3, serum galactomannan was
detected 7, 9, and 2 days before identification of the pathogen
from cultures, respectively). This is a crucial point not only for
specific diagnosis but also for the choice of antifungal therapy.
In fact, G. capitatum is susceptible to amphotericin B and
azoles, in particular voriconazole, but is intrinsically resistant
to echinocandins, which are drugs of choice for the treatment
of invasive Candida and Aspergillus infections (6). Interest-
ingly, for patient 1, infection improved when caspofungin was
replaced by voriconazole; patient 2 developed a breakthrough
G. capitatum infection while under antifungal prophylaxis with
caspofungin; and for patient 3, the choice of voriconazole
therapy was based on the observation of multiple maculopap-
ular skin lesions suggestive of disseminated Candida infection,
the positivity of the Platelia Aspergillus assay, and the experi-
ence with the previous two cases of G. capitatum infection.
In conclusion, the cases we have presented and in vitro tests
showed a previously unknown cross-reactivity of G. capitatum
with Aspergillus galactomannan. Although this cross-reactivity
may constitute a drawback for the specificity of the test, the
knowledge of this phenomenon may be useful in the diagnosis
and management of invasive G. capitatum infections, which are
rare but cause severe complications in patients with hemato-
logical malignancies.
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